Abivax to present 22 abstracts on Obefazimod for IBD at ECCO 2026, including anti-fibrotic research with oral presentation.
Abivax has revealed that 22 abstracts showcasing the evaluation of Obefazimod in Inflammatory Bowel Disease have been accepted for presentation at ECCO 2026. Among these, there will be an oral presentation highlighting preclinical anti-fibrotic findings. This event will serve as a platform to share significant findings related to Obefazimod's effectiveness in managing this condition and providing insights into potential future treatments.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments